The vice president and senior global program lead for Hematology and Cell Therapy at BMS provided an overview behind the mechanism and early phase 1 data of BMS-986353 in various forms of multiple sclerosis. [WATCH TIME: 4 minutes]
Rosanna Ricafort, MD
Advertisement
Articles by Rosanna Ricafort, MD
Advertisement
Latest Updated Articles
Early Promise and Hypothesis Behind CAR T-Cell Therapy BMS-986353 in Multiple Sclerosis: Rosanna Ricafort, MDPublished: February 28th 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency
2
Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS
3
Evolving Landscape of Myasthenia Gravis Treatment and Unmet Needs: Leila Darki, MD
4
Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C
5
